Epidemiology of hematological malignancies, Annals of Oncology, vol.18, issue.Supplement 1, pp.3-8, 2007. ,
DOI : 10.1093/annonc/mdl443
URL : https://academic.oup.com/annonc/article-pdf/18/suppl_1/i3/6672797/mdl443.pdf
Outcomes and quality of care in acute myeloid leukemia over 40 years, Cancer, vol.245, issue.(32), pp.2903-2911, 2009. ,
DOI : 10.1016/S0950-3536(11)80033-8
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine, International Journal of Cancer, vol.35, issue.1, pp.8-13, 2008. ,
DOI : 10.1128/MCB.4.10.2098
High-performance Liquid Chromatographic Analysis of Chemical Stability of 5-aza-2???-Deoxycytidine, Journal of Pharmaceutical Sciences, vol.70, issue.11 ,
DOI : 10.1002/jps.2600701112
Dacogen: summary of product characteristics Available from, 2017. ,
The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use, The Oncologist, vol.21, issue.6, pp.692-700, 2016. ,
DOI : 10.1634/theoncologist.2015-0298
Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion, Cancer Lett, vol.331, issue.1, pp.122-129, 2013. ,
Decitabine Nanoconjugate Sensitizes Human Glioblastoma Cells to Temozolomide, Molecular Pharmaceutics, vol.12, issue.4, pp.1279-1288, 2015. ,
DOI : 10.1021/mp500815b
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689316/pdf
gut permeation studies, Nanotechnology, vol.24, issue.41, pp.415102-415113, 2013. ,
DOI : 10.1088/0957-4484/24/41/415102
Lipid based nanocarrier system for the potential oral delivery of decitabine: Formulation design, characterization, ex vivo, and in vivo assessment, International Journal of Pharmaceutics, vol.477, issue.1-2, pp.601-612, 2014. ,
DOI : 10.1016/j.ijpharm.2014.11.001
Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery, Nanomedicine, vol.83, issue.2, pp.287-306, 2010. ,
DOI : 10.1152/physrev.00001.2003
A novel phase inversion-based process for the preparation of lipid nanocarriers, Pharmaceutical Research, vol.19, issue.6, pp.875-880, 2002. ,
DOI : 10.1023/A:1016121319668
Lipid nanocapsules: A new platform for nanomedicine, International Journal of Pharmaceutics, vol.379, issue.2, pp.201-209, 2009. ,
DOI : 10.1016/j.ijpharm.2009.04.026
Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration, European Journal of Pharmaceutics and Biopharmaceutics, vol.79, issue.1 ,
DOI : 10.1016/j.ejpb.2011.01.021
Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide, European Journal of Pharmaceutical Sciences, vol.50, issue.2, pp.172-180, 2013. ,
DOI : 10.1016/j.ejps.2013.06.013
Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study, PLOS ONE, vol.12, issue.2, p.141788, 2015. ,
DOI : 10.1371/journal.pone.0141788.t005
Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsules, Nanomedicine: Nanotechnology, Biology and Medicine, vol.10, issue.8, pp.1667-1677, 2014. ,
DOI : 10.1016/j.nano.2014.05.002
URL : https://hal.archives-ouvertes.fr/hal-01624361
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study, Int J Nanomedicine, vol.6, pp.2941-2951, 2011. ,
Antiepidermal growth factor receptor siRNA carried by chitosantransacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide, Int J Nanomedicine, vol.9, pp.1479-1490, 2014. ,
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting, Biomaterials, vol.31, issue.2, pp.321-329, 2010. ,
DOI : 10.1016/j.biomaterials.2009.09.044
URL : https://hal.archives-ouvertes.fr/inserm-00491402
Reverse micelle-loaded lipid nanocarriers: A novel drug delivery system for the sustained release of doxorubicin hydrochloride, European Journal of Pharmaceutics and Biopharmaceutics, vol.79, issue.1, pp.197-204, 2011. ,
DOI : 10.1016/j.ejpb.2011.02.015
Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride, International Journal of Pharmaceutics, vol.436, issue.1-2, pp.194-200, 2012. ,
DOI : 10.1016/j.ijpharm.2012.06.026
Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules, Pharmaceutical Research, vol.47, issue.6, pp.1243-1250, 2006. ,
DOI : 10.1111/j.1768-322X.1987.tb00571.x
A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12, American Journal of Epidemiology, vol.27, issue.3, pp.493-497, 1938. ,
DOI : 10.1093/oxfordjournals.aje.a118408
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines, Blood, vol.113, issue.3, pp.659-667, 2009. ,
DOI : 10.1182/blood-2008-02-140038
Stability indicating RP-HPLC method for the estimation of decitabine in bulk drug and lipid based nanoparticles, Int J Pharm Sci Res, vol.7, pp.294-302, 2014. ,
Development and validation of a HILIC???MS/MS method for quantification of decitabine in human plasma by using lithium adduct detection, Journal of Chromatography B, vol.969, pp.117-122, 2014. ,
DOI : 10.1016/j.jchromb.2014.08.012
siRNA LNCs ??? A novel platform of lipid nanocapsules for systemic siRNA administration, European Journal of Pharmaceutics and Biopharmaceutics, vol.81, issue.2, pp.448-452, 2012. ,
DOI : 10.1016/j.ejpb.2012.02.010
Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells, Journal of Controlled Release, vol.205, pp.7-14, 2015. ,
DOI : 10.1016/j.jconrel.2014.11.011
Lipid???Polymer Nanoparticles Encapsulating Doxorubicin and 2???-Deoxy-5-azacytidine Enhance the Sensitivity of Cancer Cells to Chemical Therapeutics, Molecular Pharmaceutics, vol.10, issue.5, pp.1901-1909, 2013. ,
DOI : 10.1021/mp300675c
The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability, Biomaterials, vol.31, issue.29, pp.7542-7554, 2010. ,
DOI : 10.1016/j.biomaterials.2010.06.024
Optimization of the lyophilization process for long-term stability of solid???lipid nanoparticles, Drug Development and Industrial Pharmacy, vol.38, issue.10, pp.1270-1279, 2012. ,
DOI : 10.1039/c39800000104
Influence of Lipid Nanocapsules Composition on Their Aptness to Freeze-Drying, Pharmaceutical Research, vol.70, issue.2, pp.285-292, 2005. ,
DOI : 10.1007/s11095-004-1196-0
Pharmacokinetic and pharmacodynamic analysis of 5-aza-2???-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy, Clinical Epigenetics, vol.5, issue.1, p.3, 2013. ,
DOI : 10.1002/cncr.11543
Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis, Oncotarget, vol.8, issue.25, pp.41498-41507, 2017. ,
DOI : 10.18632/oncotarget.17241
Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors, British Journal of Pharmacology, vol.321, issue.Pt 3, pp.3868-3880, 2014. ,
DOI : 10.1016/S0022-2836(02)00676-9
Cellular Uptake of Decitabine by Equilibrative Nucleoside Transporters in HCT116 Cells, Biological and Pharmaceutical Bulletin, vol.38, issue.8, pp.1113-1119, 2015. ,
DOI : 10.1248/bpb.b14-00622
Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles, International Journal of Pharmaceutics, vol.429, issue.1-2, pp.123-134, 2012. ,
DOI : 10.1016/j.ijpharm.2012.03.014
A review of the nonclinical safety of Transcutol??, a highly purified form of diethylene glycol monoethyl ether (DEGEE) used as a pharmaceutical excipient, Food and Chemical Toxicology, vol.72, pp.40-50, 2014. ,
DOI : 10.1016/j.fct.2014.06.028
Cytotoxicity and genotoxicity of lipid nanocapsules, Toxicology in Vitro, vol.41, pp.189-199, 2017. ,
DOI : 10.1016/j.tiv.2017.03.007
Surfactant dependent toxicity of lipid nanocapsules in HaCaT cells, International Journal of Pharmaceutics, vol.411, issue.1-2, pp.136-141, 2011. ,
DOI : 10.1016/j.ijpharm.2011.03.056
Recent advances in myelodysplasia: update from 2011 ASH annual meeting, Journal of Hematology & Oncology, vol.5, issue.Suppl 1, p.4, 2012. ,
DOI : 10.1182/blood-2011-09-377275
URL : https://doi.org/10.1186/1756-8722-5-s1-a4
Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis, Journal of Controlled Release, vol.140, issue.2, pp.174-181, 2009. ,
DOI : 10.1016/j.jconrel.2009.08.010
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine, Blood, vol.119, issue.5, pp.1240-1247, 2012. ,
DOI : 10.1182/blood-2011-08-371690
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study, The Lancet Oncology, vol.16, issue.9, pp.1099-1110, 2015. ,
DOI : 10.1016/S1470-2045(15)00038-8
Lipid nanocapsules maintain full integrity after crossing a human intestinal epithelium model, Journal of Controlled Release, vol.253, pp.11-18, 2017. ,
DOI : 10.1016/j.jconrel.2017.03.005